CenterWatch

Clinical Trial Details

NCT ID: NCT00686348
Date Last Changed: November 25, 2014

Overview

Research Study Summary

Patients are needed to participate in a clinical research study for the treatment of Acromegaly

Research Study Title

Somatuline® Depot (Lanreotide) Injection for Acromegaly (SODA): A Post-marketing Observational Study

Purpose

To assess the safety and effectiveness of Somatuline® Depot (lanreotide) Injection when administered by a health care professional (HCP), the patient, the patient's partner or parent/guardian as part of their routine acromegaly care.

To Learn more

Recruitment Details

Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Lead Sponsor
Ipsen
Duration
79 Months
Facility Type
N/A
Compensation

Eligibility

Both Male and Female ages up to N/A

Inclusion Criteria:

  • The patient must have a clinical diagnosis of acromegaly

  • The patient must be treated with Somatuline® Depot (including patients newly prescribed Somatuline® Depot)

  • The patient or legally authorized representative must be able to understand the protocol and give signed informed consent. Assent from the patient should also be obtained, where appropriate. Signed informed consent and assent must be obtained before any study-related activities are conducted.

Exclusion Criteria:

  • Symptomatic, untreated biliary lithiasis

  • Known hypersensitivity to somatostatin analogs or related compounds (e.g., octreotide)

Site Locations (1)

Country State City Zip Facility and Contact
United States New Jersey Basking Ridge 07920 Ipsen

Contact

Ipsen Central Contact

E-mail:

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.